- Home
- RC vs NTLA Comparison
RC vs NTLA Comparison
Compare RC & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RC
- NTLA
- Stock Information
- Founded
- RC 2007
- NTLA 2014
- Country
- RC United States
- NTLA United States
- Employees
- RC N/A
- NTLA N/A
- Industry
- RC Real Estate Investment Trusts
- NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- RC Real Estate
- NTLA Health Care
- Exchange
- RC Nasdaq
- NTLA Nasdaq
- Market Cap
- RC 1.2B
- NTLA 1.4B
- IPO Year
- RC N/A
- NTLA 2016
- Fundamental
- Price
- RC $7.26
- NTLA $12.18
- Analyst Decision
- RC Hold
- NTLA Buy
- Analyst Count
- RC 10
- NTLA 17
- Target Price
- RC $29.25
- NTLA $56.63
- AVG Volume (30 Days)
- RC 2.0M
- NTLA 2.4M
- Earning Date
- RC 11-07-2024
- NTLA 02-20-2025
- Dividend Yield
- RC 13.77%
- NTLA N/A
- EPS Growth
- RC N/A
- NTLA N/A
- EPS
- RC N/A
- NTLA N/A
- Revenue
- RC $140,359,000.00
- NTLA $43,086,000.00
- Revenue This Year
- RC N/A
- NTLA $52.50
- Revenue Next Year
- RC $13.62
- NTLA $0.42
- P/E Ratio
- RC N/A
- NTLA N/A
- Revenue Growth
- RC N/A
- NTLA N/A
- 52 Week Low
- RC $6.65
- NTLA $11.79
- 52 Week High
- RC $11.11
- NTLA $34.87
- Technical
- Relative Strength Index (RSI)
- RC 48.69
- NTLA 34.42
- Support Level
- RC $7.17
- NTLA $11.79
- Resistance Level
- RC $7.64
- NTLA $13.79
- Average True Range (ATR)
- RC 0.22
- NTLA 0.85
- MACD
- RC -0.03
- NTLA -0.14
- Stochastic Oscillator
- RC 40.63
- NTLA 9.97
About RC Ready Capital Corproation
Ready Capital Corp is a real estate finance company. It acquires, manages, originates, and finances small-balance commercial loans to purchase small multi-family, office, retail, mixed-use, or warehouse properties. The company's segments consist of LMM Commercial Real Estate and Small Business Lending. It generates the majority of its revenue from LMM Commercial Real Estate.
About NTLA Intellia Therapeutics Inc.
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.